Cholesterol absorption inhibitors, which decrease the amount of cholesterol absorbed from food and lower triglycerides. (medlineplus.gov)
Statins4
In the last few years, statins, HMG-coenzyme A reductase inhibitors, became an important class of drugs, widely used in clinics to treat dyslipidemia. (aspetjournals.org)
RESULTS: Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). (uu.nl)
Purpose of Review: Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the liver and reduce atherosclerotic cardiovascular disease (ASCVD) risk by enhancing low-density lipoprotein (LDL) clearance from the circulation. (aku.edu)
Nevertheless, rhabdomyolysis has been reported, and coadministration of daptomycin with other drugs associated with myopathy, such as hydroxymethylglutaryl CoA reductase inhibitors (statins), may increase risk. (msdmanuals.com)
Coenzyme A reductase1
It has been shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition blocks hypertrophy, and we report here that "statin" therapy effectively suppresses small G protein activation and blunts hypertrophic growth in vitro and in vivo. (tamu.edu)
Atorvastatin1
LIPITOR (atorvastatin) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. (hipaaspace.com)
Mesh1
Une recherche documentaire a été effectuée dans PubMed de 1980 à 2021 en utilisant diverses combinaisons de termes MeSH comme tabac, diabète, hypertension, dyslipidémie, trouble dépressif majeur, trouble bipolaire, schizophrénie. (bvsalud.org)
Because this information could be of substantial clinical relevance, we addressed this question in patients with type 2 diabetes and combined dyslipidemia by comparing the effects of gemfibrozil versus HMG-CoA reductase inhibitors (statins) on both fasting and postprandial lipid and lipoprotein concentrations. (nih.gov)
The statin drugs ('statins') potently inhibit hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by competitively blocking the active site of the enzyme. (nih.gov)
Nevertheless, rhabdomyolysis has been reported, and coadministration of daptomycin with other drugs associated with myopathy, such as hydroxymethylglutaryl CoA reductase inhibitors (statins), may increase risk. (msdmanuals.com)
Conclusion: use of ACE inhibitors, statins or thiazides was not associated with differences in grip strength decline in healthy older people in the HCS. (dundee.ac.uk)
In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. (uni-luebeck.de)
Atorvastatin1
The effect of erythromycin on the pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase, was investigated in 12 healthy volunteers. (nih.gov)
Pravastatin1
Other inhibitors of rOatps (taurocholate and pravastatin) and rOat3 (pravastatin and p -aminohippurate) had a slight effect, but digoxin had no effect. (aspetjournals.org)
MeSH1
Une recherche documentaire a été effectuée dans PubMed de 1980 à 2021 en utilisant diverses combinaisons de termes MeSH comme tabac, diabète, hypertension, dyslipidémie, trouble dépressif majeur, trouble bipolaire, schizophrénie. (bvsalud.org)
Cholesterol2
Background Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. (uni-luebeck.de)
We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. (uni-luebeck.de)
Statin1
We therefore examined the association of angiotensin converting enzyme (ACE) inhibitor, thiazide and statin use with decline in grip strength in a well-characterised cohort. (dundee.ac.uk)
Simvastatin2
1. In the present study, we tested the hypothesis that long-term administration of the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin may regress hypertrophy and the possible effect of simvastatin on angiotensin-converting enzyme (ACE) activity in rats with pressure-overload cardiac hypertrophy. (nih.gov)
In the simvastatin-treated and ACE inhibitor groups all these parameters were significantly reduced compared with sham-operated controls. (nih.gov)
Angiotensin1
Use of guideline-directed medical therapy (GDMT) similar to patients with HF and without diabetes, including an angiotensin receptor-neprilysin inhibitor (ARNI) (or ACEi/ARB if ARNI is not prescribed), evidence-based beta-blockers, mineralocorticoid receptor antagonists, and SGLT2is. (acc.org)
PCSK91
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. (nih.gov)
Immune checkpoint1
Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have opened up a new venue of advanced cancer immunotherapy. (bvsalud.org)
Therapy2
The threat of rhabdomyolysis with dual pharmacologic treatment (hepatic hydroxymethyl glutaryl coenzyme A [HMG-CoA] reductase inhibitors plus fibric acid derivatives) has tended to limit therapy in patients with combined dyslipidemia to a choice of one or the other drug. (nih.gov)
Hyperlipidemia: Familial hypercholesterolemia is managed with a hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor, which is the mainstay of therapy and may be used in combination with other agents. (medscape.com)
Chronic1
Chronic intracerebroventricular infusion of lysosomal inhibitors blocked these effects, indicating that up-regulation of the lysosomal degradation of endogenous APP-CTFs is involved in reduced Aβ production. (nih.gov)
Treatment1
Thus, HMG-CoA reductase inhibitors may be beneficial for the clinical treatment of cardiac hypertrophy. (nih.gov)
Significantly1
The uptake of ketoprofen by hepatocytes was significantly inhibited by probenecid and rOat2 inhibitors (indocyanine green, indomethacin, glibenclamide, and salicylate). (aspetjournals.org)
Disease1
However, hyperprogressive disease (HPD) induced by PD-1/PD-L1 inhibitors caused a significant decrease in the overall survival (OS) of the patients, which compromise the efficacy of PD-1/PD-L1 inhibitors. (bvsalud.org)
Activity2
Both hydrolysates (tested in the concentration range of 0.5-2.5 mg/mL) inhibited the 3-hydroxy-3-methylglutaryl-CoA reductase activity in HepG2 cells. (uniroma5.it)